Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The Company issued 426,848 shares of Common Stock (with an additional 5,184 shares pending issuance) to satisfy an earn-out obligation under the Prevu acquisition merger agreement. The shares were issued pursuant to Section 4(a)(2) and Rule 506 of Regulation D as an unregistered private placement to accredited investors. This is a classic dilutive issuance under Item 3.02, representing a material increase in share count (approximately 7.3% dilution based on the post-issuance outstanding count of 5,861,724 shares) and a direct financial obligation satisfied through equity rather than cash.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-06
EX-99.1
The news release announces final TSX Venture Exchange approval and receipt of funds from a "non-brokered private placement" previously disclosed on July 16, 2026. Non-brokered private placements are unregistered equity issuances that dilute existing shareholders. The announcement confirms completion of the offering and receipt of proceeds, making this a material capital-raising event typical of small-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities on August 6, 2026, authorizing the sale of up to $75 million in common stock through an "at the market" offering under Rule 415. This is a dilutive equity issuance that provides the company with a capital-raising mechanism and would materially affect existing shareholders through potential dilution. The substantial offering size and explicit authorization to sell shares make this a material capital event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-06
Item 2.03
Item 2.03 discloses an issuance of shares relying on Section 4(a)(2) exemption (private placement), with restricted legend shares issued to sophisticated investors with no general solicitation. The disclosure of unregistered equity issuance under Item 2.03 is characteristic of dilutive private placements, which are material events affecting shareholder equity and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02 discloses an unregistered sale of 251,666 shares of common stock to White Lion Capital, LLC at prices ranging from $2.79 to $2.90 per share for approximately $716,000 in gross proceeds. The shares were issued under Section 4(a)(2) exemption, which is a classic private placement structure. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses an unregistered sale of 92,960.33 common shares across multiple classes for approximately $1.895 million on August 3, 2026, exempt under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities to third-party investors, directly matching the Item 3.02 disclosure requirement and the dilutive_issuance event type. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
Silvaco issued conversion shares underlying the $10.0 million convertible note in a private placement under Section 4(a)(2) exemption, with the securities offered and sold as unregistered securities creating potential equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-06
Item 3.02
On July 31, 2026, Valion Bio entered into a Securities Purchase Agreement with Statera and Avenue Venture Opportunities Fund, issuing 1,287.8685 shares of Series A Preferred Stock as consideration for a Milestone Payment. The shares are unregistered, restricted securities issued under Section 4(a)(2) and Regulation D exemptions to accredited investors, materially diluting existing shareholder ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-06
Item 1.01
UWM entered into a securities purchase agreement on August 5, 2026, issuing 1.65 billion warrants (Class A and Class B) plus 1.5 million Series A-1 and 150,000 Series A-2 preferred shares for $1.65 billion in gross proceeds from Oaktree Capital Management and the Ishbia family. The transaction includes a rights offering to distribute up to 200 million shares of Class A Common Stock for at least $400 million in aggregate proceeds, fully backstopped by the Ishbia Purchaser.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Tarsus Pharmaceuticals completed a private placement (PIPE) of approximately $125.0 million, consisting of 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase 133,625 additional shares at $0.0001 per share. The unregistered securities were sold to qualified institutional buyers and accredited investors under Section 4(a)(2) of the Securities Act, with registration rights to be granted under a Registration Rights Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The company issued approximately $12.2 million in unregistered equity securities across two separate transactions in June and July 2026, across multiple share classes (E, AA, I-S, F, FF, A) to investors and as compensation to Sculptor Advisors LLC and independent directors, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
North Haven Net REIT sold 2,790,195 common shares for approximately $58.3 million in an unregistered private offering under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance that raises capital through unregistered securities sales, materially affecting shareholder ownership and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
Franklin BSP Real Estate Debt, Inc. sold 339,562.25 shares of multiple classes of common stock (Class G, Class G-D, Class G-S, and Class I) on August 3, 2026, for aggregate consideration of $8,413,717 in a continuous private offering exempt from registration under Section 4(a)(2) and Regulation D. This is a classic unregistered equity issuance disclosed under Item 3.02, materially dilutive to existing shareholders and a significant capital raise for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 8.01
Prologis entered into an underwriting agreement on August 4, 2026 for a registered public offering of 15,000,000 shares of common stock, generating approximately $2.1 billion in net proceeds (or $2.4 billion with the underwriters' over-allotment option). This is a material registered equity issuance that dilutes existing shareholders. The filing explicitly discloses the offering is expected to close on August 5, 2026, and the proceeds will be contributed to the Operating Partnership for general corporate purposes, including potential acquisitions such as SEGRO plc.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 1.01
Twist Bioscience completed a registered public offering of 3,125,000 shares of common stock at $96.00 per share, with underwriters exercising their option to purchase an additional 468,750 shares, generating approximately $327.1 million in net proceeds. The offering was upsized from an initially proposed $250.0 million and will dilute existing shareholders while providing capital for R&D, manufacturing expansion, and general corporate purposes.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-05
NetClass Technology issued 100,000 Class B Ordinary Shares to Dragonsoft Holding Limited (controlled by CEO Dr. Jianbiao Dai) on August 5, 2026, pursuant to a securities purchase agreement dated August 1, 2026. The issuance was made under Section 4(a)(2) exemption, indicating an unregistered private placement. Post-issuance, the Buyer holds 100% of Class B shares representing 77.93% of total voting power, constituting a material dilutive equity issuance to an insider-controlled entity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 3.02
Campbell Fund Trust sold unregistered Units of Beneficial Interest totaling approximately $5.18 million across three series (A, D, and W) on July 31, 2026, in reliance on Section 4(2) of the Securities Act and Regulation D. This is a classic private placement of equity securities exempt from registration, which dilutes existing unitholders and represents a material capital-raising event for the fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
The Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC authorizing the issuance and sale of up to $200.0 million in shares of Common Stock through an at-the-market offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 1.01
ZW Data Action Technologies Inc. entered into five Securities Purchase Agreements on July 30, 2026, to sell an aggregate of 1,000,000 shares of common stock at $1.45 per share for a total of $1,450,000 in a private placement of unregistered equity securities to accredited investors under Section 4(a)(2) and Regulations D and S. This unregistered issuance will dilute existing shareholders' ownership and materially affect the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 3.02
Mitesco issued approximately 11.1 million shares of unregistered restricted common stock across five tranches (gifts, software developer compensation, advisory agreement, consulting services, and board director compensation), increasing outstanding shares from approximately 36 million to 47 million—a 31% dilution. The securities are unregistered and may not be offered or sold absent registration or exemption.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
The Company completed a registered public offering of 1,086,957 shares of common stock on July 30, 2026, with an additional 260,869 option shares exercised and purchased on August 5, 2026, generating approximately $14.1 million in gross proceeds. This represents a material dilutive issuance of registered equity securities under a Form S-3 registration statement, with proceeds earmarked for capital expenditures, working capital, and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-08-05
Item 1.01
FTC Solar entered into a Lincoln Park Capital Purchase Agreement on August 4, 2026, establishing an equity line of credit for up to $20 million of common stock and issuing 60,145 commitment shares as consideration. The company will issue additional shares under the ELOC arrangement in reliance on Section 4(a)(2) and Rule 506(b) exemptions, providing flexible equity financing typical of small- to mid-cap companies.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
Easterly Government Properties filed a prospectus supplement on August 4, 2026 updating its "at the market" (ATM) equity offering program under a shelf registration statement, with $214,982,308 remaining available for sale. The company also entered into amended equity distribution agreements with nine sales agents and master forward confirmations with financial institutions to facilitate both direct share sales and contingent/non-contingent forward transactions. This is a classic dilutive equity issuance disclosure under Item 3.02, involving an ATM program that permits continuous offerings of common stock and forward sale arrangements that will result in share dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses an unregistered sale of 1,113,414.907 common shares for approximately $22.3 million under Section 4(a)(2) and Regulation D, which is a classic private placement. The sale occurred on August 3, 2026, as part of the Company's continuous private offering. This is a material capital-raising event that dilutes existing shareholders and is reportable under Item 3.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses an unregistered sale of 21,060 Class D Common Shares generating $581,000 in gross proceeds under a continuous private placement offering of up to $2.165 billion. The Company explicitly states it is relying on Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D—classic exemptions for private placements. This is a textbook dilutive issuance under Item 3.02, material because it represents equity capital raising and potential shareholder dilution in an ongoing offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
BOA Acquisition Corp. II completed a private placement of 221,500 units at $10.00 per unit for $2,215,000 to the Sponsor and Private Placement Investors, concurrent with the IPO closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
The Company filed a new Form S-3 shelf registration statement and four prospectus supplements to continue offerings of common stock, including an "at the market" (ATM) offering program with up to $500 million in aggregate offering price and $288.5 million remaining available for sale. The filing also covers potential issuances of common stock upon redemption of partnership units. This is a classic dilutive equity issuance disclosure under Item 8.01, material to investors as it signals potential capital raising and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
Xenia Hotels entered into an at-the-market (ATM) equity distribution agreement on August 5, 2026, authorizing the offer and sale of up to $200 million of common stock through multiple sales agents and forward sellers. This is a classic dilutive equity issuance disclosed under Item 8.01, involving both direct sales and forward sale arrangements that will result in shareholder dilution. The filing explicitly references the shelf registration statement and prospectus supplement filed to support these offerings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Postal Realty Trust entered into sales agreements on August 5, 2026 with multiple financial institutions to offer and sell up to $300 million of Class A common stock through an at-the-market offering program, including forward sale agreements. This is a material dilutive equity issuance that would affect investor assessment of share dilution and capital structure. The filing explicitly describes the mechanics of ordinary brokers' transactions, forward sale agreements (both contingent and non-contingent), and the company's receipt of net proceeds, which are hallmarks of a registered equity offering program.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-05
EX-99.1
This press release announces a private placement of 1,000,000 ordinary shares and warrants to purchase 1,000,000 additional shares for approximately $3.3 million gross proceeds. The offering is structured as an unregistered sale under Section 4(a)(2) of the Securities Act, which is a classic dilutive issuance. The company has agreed to file a registration statement for resale, and the warrants are immediately exercisable, both hallmarks of a dilutive capital raise at a small-cap issuer.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
ISQ Open Infrastructure Co LLC completed unregistered sales of equity securities totaling $16,266,500 across Series I and Series II share classes as of July 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
McKinley Acquisition Corp. disclosed an unregistered private placement (PIPE) of $75 million in senior secured convertible notes, warrants, and underlying shares of common stock representing 9.9% of McKinley's outstanding common stock post-merger, issued under Section 4(a)(2) and Regulation D Rule 506.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-05
The Company closed a registered offering of 15,000,000 Class A ordinary shares at $1.00 per share on August 4, 2026, raising approximately $14.562 million in net proceeds. This is a material equity issuance registered under Form F-1, disclosed under the heading "Closing of a Material Transaction" and would materially dilute existing shareholders' ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses unregistered issuance of 1,550,000 shares of common stock in exchange for consulting services under Section 4(a)(2) exemption. This is a classic dilutive equity issuance to service providers, material to investors as it increases share count and dilutes existing shareholders. The Item 3.02 designation and explicit reference to Section 4(a)(2) private placement exemption confirm the dilutive_issuance classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses an unregistered sale of 256,649.746 shares of common stock at $9.85 per share for an aggregate offering price of $2,528,000, conducted pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D. This is a classic private placement that dilutes existing shareholders and represents a material capital-raising event for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-05
Item 3.02
Alternus Clean Energy issued 14,280 shares of Series F Convertible Preferred Stock with a total face value of $14,280,000 to 15 accredited investors pursuant to subscription agreements on August 5, 2026, under Section 4(a)(2) and Regulation D Rule 506(b). The convertible preferred shares are dilutive to existing shareholders and represent a material private placement to raise capital and restructure obligations including debt extension, advisory board appointments, consulting agreements, and interest forgiveness.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-08-05
EX-99.1
The exhibit discloses a non-brokered private placement with issuance of 2,150,569 units (1,030,000 units at $0.15 per unit plus 1,120,569 units issued to settle debt) comprising common shares and warrants. This is a dilutive equity issuance typical of small-cap companies raising capital. While the filing also announces a name change to "Dune Oil Corp." and strategic pivot, the material financial event is the private placement closing, which increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-05
Item 1.01
My Size, Inc. entered into an Equity Purchase Agreement dated August 5, 2026, with Square Gate Master Fund, LLC for the issuance of Commitment Shares to an accredited investor under Section 4(a)(2) and Regulation D Rule 506(b) exemptions. The unregistered private placement increases share count and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-05
Glucotrack disclosed entry into definitive agreements on August 4, 2026 for approximately $5.5 million in follow-on financing, consisting of (i) a $3.5 million Bridge Follow-On via convertible promissory notes and warrants, and (ii) a $2.0 million Interim PIPE involving pre-funded warrants and common stock purchase warrants. The filing explicitly covers Items 1.01 (Entry Into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), and 3.02 (Unregistered Sales of Equity Securities), with the equity component priced at $0.75 per unit and warrant exercise prices of $1.50 per share. This is a classic dilutive private placement raising capital through unregistered equity issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses unregistered issuances of common stock totaling over 1 million shares across five separate transactions (July 29–August 4, 2026) in exchange for preferred stock held by existing security holders. The Company relied on Section 3(a)(9) of the Securities Act for the exemption. This represents a substantial dilutive issuance to existing shareholders, with the conversion ratios ranging from 7:1 to 146:4 common-to-preferred shares, and would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-05
Item 1.01
A10 Networks issued a warrant to Microsoft granting the right to purchase up to 800,000 shares at $0.01 per share, with vesting based on Microsoft's product purchases and exercisability starting in 2028-2029. This unregistered equity issuance represents a dilutive transaction that will dilute existing shareholders upon exercise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The Company issued and sold 45,093 shares of common stock for $45.00 million on July 1, 2026, pursuant to a subscription agreement in reliance on Section 4(a)(2) of the Securities Act and Regulation D—a classic unregistered private placement. This is a material capital-raising event for the fund that dilutes existing shareholders and is disclosed under Item 3.02 (Unregistered Sales of Equity Securities).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The Company issued 425,765 common shares for approximately $8.6 million under Section 4(a)(2) and Regulation D Rule 506, and issued 3,509.10 Class E Common Shares to an affiliate as payment for advisory fees. These unregistered equity issuances are dilutive to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses an unregistered sale of 1,817,941 Class S-2 shares for approximately $26.6 million under Section 4(a)(2) and Regulation D. This is a classic dilutive private placement to accredited investors, which is material to shareholders as it increases share count and dilutes existing ownership. The transaction is properly classified under Item 3.02 (Unregistered Sales of Equity Securities).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
The filing discloses an unregistered sale of equity securities across multiple share classes (Class B, R-I, R-S, and M-I) totaling approximately $2.6 million in aggregate consideration on August 3, 2026. The securities were issued pursuant to Section 4(a)(2) and Regulation D exemptions, which are characteristic of private placements. This is a dilutive issuance of unregistered equity that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 15,070,694 common shares for approximately $161.4 million on August 3, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-04
Item 1.01
Pinnacle West Capital Corporation entered into an Equity Distribution Agreement on August 4, 2026, authorizing the issuance and sale of up to $500 million in common stock shares through an at-the-market offering and forward sale agreements. This is a material dilutive equity issuance that will increase the share count and is registered under the Securities Act. The agreement includes both direct sales through managers and forward sale agreements with multiple financial institutions, representing a significant capital-raising transaction that would materially affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-04
Item 8.01
Ameren Corporation increased its equity distribution program by $2 billion, expanding the aggregate authorized gross sales price to $2.27 billion for potential issuance of common stock through multiple sales agents and forward sellers. This represents a material expansion of the company's capacity to issue dilutive equity securities, which is a key indicator of capital-raising activity and potential shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-04
Item 3.02
This Item 3.02 discloses the issuance of 34,376,167 shares of common stock to the Company's Chairman upon conversion of $105.8 million in convertible promissory notes. Although technically exempt from registration under Section 3(a)(9) as an exchange with an existing security holder, this represents a substantial dilutive equity issuance that materially increases share count (from ~66.5M to ~100.8M shares, a 52% increase) and significantly increases the Chairman's ownership stake to 44.3% of voting power. The conversion eliminates substantial debt but creates substantial dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-04
Item 3.02
The Fund issued 5,795,000 unregistered Class IF limited partnership units for approximately $145 million on August 3, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors and qualified purchasers.
View raw filing on EDGAR →